title: Peginterferon plus Chinese herbal therapy is associated with a higher virological response than only peginterferon therapy in chronic hepatitis C.
abstract: Traditional Chinese herbal therapies are widely used for the treatment of chronic hepatitis C (CHC) in China and several Asian countries. The aim of this study was to perform a meta-analysis of randomized controlled trials (RCTs) comparing peginterferon therapy with peginterferon plus Chinese herbal therapy for the treatment of CHC. The Cochrane Central Register of Controlled Trials, Medline, Science Citation Index, EMBASE, China National Knowledge Infrastructure, Wanfang Database, and China Biomedical Database were searched to identify RCTs that evaluated the virological response of CHC patients to peginterferon therapy and peginterferon plus Chinese herbal therapy. We statistically combined data using a fixed-effects meta-analysis according to the intention-to-treat principle. The literature search yielded 905 studies and nine RCTs composed of 858 patients matched the selection criteria. Overall, sustained virological response (SVR) was significantly higher in patients treated with peginterferon plus Chinese herbs than in patients treated with peginterferon alone (81 % vs. 64 %, respectively; odds ratio, 2.60; 95 % confidence interval: 1.32–5.14; p < 0.05). A combined therapy of peginterferon plus Chinese herbs was also superior to peginterferon therapy in achieving an early viral response (EVR, 80 % vs. 70 %, respectively), a viral response at week 24 of treatment (82 % vs. 73 %, respectively), and end-of-treatment viral response (ETVR, 73 % vs. 62 %, respectively). The combined therapy resulted in fewer relapses, fewer adverse events, and more rapid alanine transaminase normalization; however, both treatments yielded a similar rapid viral response (RVR, 53 % vs. 57 %, respectively). The current evidence suggests that combined therapy of peginterferon plus Chinese herbs yields a higher viral response and results in fewer relapses and fewer adverse events than peginterferon therapy alone.
authors.forename: D
authors.initials: D
authors.lastname: Cheng
authors.forename: E
authors.initials: E
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: R
authors.initials: R
authors.lastname: Liu
authors.forename: L
authors.initials: L
authors.lastname: Bai
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Chu
authors.forename: M
authors.initials: M
authors.lastname: Wu
authors.forename: G
authors.initials: G
authors.lastname: Cheng
authors.forename: S
authors.initials: S
authors.lastname: Zhao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D004365:Drugs, Chinese Herbal; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a
references.citation: Ann Intern Med. 2000 Feb 15;132(4):296-305
references.pmid: 10681285
references.citation: N Engl J Med. 2001 Jul 5;345(1):41-52
references.pmid: 11439948
references.citation: Antiviral Res. 2011 Feb;89(2):156-64
references.pmid: 21167210
references.citation: J Hepatol. 1999 May;30(5):956-61
references.pmid: 10365827
references.citation: Aliment Pharmacol Ther. 2004 Nov 1;20(9):931-8
references.pmid: 15521839
references.citation: Ann Intern Med. 2004 Mar 2;140(5):346-55
references.pmid: 14996676
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: Hepatology. 1997 Sep;26(3 Suppl 1):15S-20S
references.pmid: 9305658
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Int J Clin Pract. 2009 Sep;63(9):1334-9
references.pmid: 19691617
references.citation: J Hepatol. 2011 Jul;55(1):69-75
references.pmid: 21145856
references.citation: J Gastroenterol Hepatol. 2000 May;15 Suppl:E67-70
references.pmid: 10921385
references.citation: J Altern Complement Med. 2006 Oct;12(8):805-12
references.pmid: 17034287
references.citation: Eur J Clin Microbiol Infect Dis. 2011 Jan;30(1):51-7
references.pmid: 20827497
references.citation: Ann Intern Med. 2002 Feb 19;136(4):288-92
references.pmid: 11848726
references.citation: Sidahora. 2002;(4):8-10
references.pmid: 12703472
references.citation: J Gastroenterol Hepatol. 2007 Jun;22(6):832-6
references.pmid: 17565637